You are now leaving www.kedrion.at. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion grows in North America as it completes acquisition of Prometic

Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency

read more 

CORPORATE

Kedrion stronger in North America and further committed to rare diseases

Agreement with Canadian-based Liminal BioSciences signed on June 22nd

read more 

CORPORATE

Kedrion announces the appointment of a new CEO

Val Romberg from the USA, one of the most esteemed managers in the industry

read more 
  1. CORPORATE - 18-10-2021

    Kedrion grows in North America as it completes acquisition of Prometic

    Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency

    read more 
  2. CORPORATE - 30-06-2021

    Kedrion stronger in North America and further committed to rare diseases

    Agreement with Canadian-based Liminal BioSciences signed on June 22nd

    read more 
  3. CORPORATE - 06-10-2020

    Kedrion announces the appointment of a new CEO

    Val Romberg from the USA, one of the most esteemed managers in the industry

    read more 
  4. CORPORATE - 22-07-2020

    COVID-19. Kedrion partners with Columbia University Irving MC

    Kedrion and Columbia University release video statements

    read more 

Pages

For more information please contact: [email protected]